Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution
作者: Naoki FujitaTakuya KoieChikara OhyamaYoshimi TanakaOsamu SomaTeppei MatsumotoHayato YamamotoAtsushi ImaiYuki TobisawaTohru YoneyamaShingo HatakeyamaYasuhiro Hashimoto
作者单位: 1Hirosaki University Graduate School of Medicine
刊名: International Journal of Clinical Oncology, 2017, Vol.22 (6), pp.1087-1093
来源数据库: Springer Journal
DOI: 10.1007/s10147-017-1160-8
关键词: Prostate cancerRadical prostatectomyNeoadjuvant chemohormonal therapyEstramustine phosphateOverall survival
英文摘要: The optimal treatment for high-risk prostate cancer (PCa) remains to be established. We previously reported favorable, biochemical recurrence-free survival in high-risk PCa patients treated with a neoadjuvant gonadotropin-releasing hormone agonist or antagonist and estramustine phosphate (EMP) (chemohormonal therapy; CHT) followed by radical prostatectomy (RP). We conducted a retrospective study to elucidate the clinical benefit of neoadjuvant CHT for high-risk PCa patients.
原始语种摘要: The optimal treatment for high-risk prostate cancer (PCa) remains to be established. We previously reported favorable, biochemical recurrence-free survival in high-risk PCa patients treated with a neoadjuvant gonadotropin-releasing hormone agonist or antagonist and estramustine phosphate (EMP) (chemohormonal therapy; CHT) followed by radical prostatectomy (RP). We conducted a retrospective study to elucidate the clinical benefit of neoadjuvant CHT for high-risk PCa patients.
全文获取路径: Springer  (合作)
分享到:
来源刊物:
影响因子:1.727 (2012)

×
关键词翻译
关键词翻译
  • prostatectomy 前列腺切除术
  • survival 生存
  • radical 
  • estramustine 雌氮芥
  • cancer 癌症
  • phosphate 磷酸盐
  • therapy 治疗
  • gonadotropin 促性腺激素
  • recurrence 循环
  • favorable 好意的